HK1246641A1 - 緩釋性醫藥組合物 - Google Patents

緩釋性醫藥組合物

Info

Publication number
HK1246641A1
HK1246641A1 HK18106001.4A HK18106001A HK1246641A1 HK 1246641 A1 HK1246641 A1 HK 1246641A1 HK 18106001 A HK18106001 A HK 18106001A HK 1246641 A1 HK1246641 A1 HK 1246641A1
Authority
HK
Hong Kong
Prior art keywords
sustained
pharmaceutical composition
release pharmaceutical
release
composition
Prior art date
Application number
HK18106001.4A
Other languages
English (en)
Inventor
岡部高明
藤澤豐實
山田和人
Original Assignee
參天製藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 參天製藥株式會社 filed Critical 參天製藥株式會社
Publication of HK1246641A1 publication Critical patent/HK1246641A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18106001.4A 2015-03-18 2018-05-09 緩釋性醫藥組合物 HK1246641A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015055196 2015-03-18
PCT/JP2016/058455 WO2016148228A1 (ja) 2015-03-18 2016-03-17 徐放性医薬組成物

Publications (1)

Publication Number Publication Date
HK1246641A1 true HK1246641A1 (zh) 2018-09-14

Family

ID=56919076

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18104433.7A HK1245083A1 (zh) 2015-03-18 2018-04-03 緩釋性醫藥組合物
HK18106001.4A HK1246641A1 (zh) 2015-03-18 2018-05-09 緩釋性醫藥組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18104433.7A HK1245083A1 (zh) 2015-03-18 2018-04-03 緩釋性醫藥組合物

Country Status (12)

Country Link
US (1) US11090296B2 (zh)
EP (1) EP3272362B1 (zh)
JP (2) JP2016175900A (zh)
KR (2) KR20230104762A (zh)
CN (1) CN107427587A (zh)
AR (1) AR105947A1 (zh)
CA (1) CA2979971A1 (zh)
ES (1) ES2969514T3 (zh)
HK (2) HK1245083A1 (zh)
RU (1) RU2704813C2 (zh)
TW (1) TWI731853B (zh)
WO (1) WO2016148228A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2704813C2 (ru) * 2015-03-18 2019-10-31 Сантен Фармасьютикал Ко., Лтд. Фармацевтическая композиция с пролонгированным высвобождением
AU2017290143A1 (en) * 2016-06-30 2019-02-21 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
EA201990127A1 (ru) * 2016-12-30 2020-08-18 Дьюрект Корпорейшн Депо-препарат
CN112423740A (zh) 2018-05-01 2021-02-26 奇比有限公司 用于将药物持续递送至视网膜的滴眼剂制剂和方法
CA3097927A1 (en) 2018-05-01 2019-11-07 Chibi, Inc. Liquid depot for non-invasive sustained delivery of agents to the eye

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001388A (en) * 1973-06-14 1977-01-04 Alza Corporation Ophthalmological bioerodible drug dispensing formulation
US5980945A (en) * 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US20050281879A1 (en) * 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
EP1717229B1 (en) * 2004-02-17 2011-06-15 Santen Pharmaceutical Co., Ltd. Novel cyclic compound having 4-pyridylalkylthio group having (un)substituted amino introduced therein
CA2582096C (en) 2004-10-01 2014-01-07 Ramscor, Inc. Conveniently implantable sustained release drug compositions
CA2582374A1 (en) 2004-10-04 2006-04-20 Qlt Usa, Inc. Ocular delivery of polymeric delivery formulations
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060258698A1 (en) * 2005-02-09 2006-11-16 Sreenivasu Mudumba Liquid formulations for treatment of diseases or conditions
CN101677952B (zh) 2007-05-18 2012-12-05 杜雷科特公司 改进的贮库制剂
CN101827523A (zh) * 2007-08-16 2010-09-08 马库赛特公司 用于治疗眼部疾病或病症的制剂
EA019689B1 (ru) 2009-07-17 2014-05-30 Сантен Фармасьютикал Ко., Лтд. Бензолсульфонат 2-[[[2-[(гидроксиацетил)амино]-4-пиридинил]метил]тио]-n-[4-(трифторметокси)фенил]-3-пиридинкарбоксамида, его кристаллы, его полиморфы и способы их получения
MX359119B (es) * 2011-06-10 2018-09-14 Ramscor Inc Formulaciones de liberación sostenida para el suministro de proteínas al ojo y métodos para prepararlas.
CA2869377C (en) 2012-04-09 2022-11-08 Scidose, Llc Fulvestrant formulations
KR20160060656A (ko) * 2013-09-20 2016-05-30 산텐 세이야꾸 가부시키가이샤 폴리에틸렌글리콜 함유 조성물
JP2016104708A (ja) * 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
RU2704813C2 (ru) * 2015-03-18 2019-10-31 Сантен Фармасьютикал Ко., Лтд. Фармацевтическая композиция с пролонгированным высвобождением
US10682340B2 (en) * 2016-06-30 2020-06-16 Durect Corporation Depot formulations
AU2017290143A1 (en) * 2016-06-30 2019-02-21 Durect Corporation Depot formulations

Also Published As

Publication number Publication date
JP2020117522A (ja) 2020-08-06
JP6955604B2 (ja) 2021-10-27
JP2016175900A (ja) 2016-10-06
US20180042907A1 (en) 2018-02-15
RU2704813C2 (ru) 2019-10-31
RU2017134354A3 (zh) 2019-04-19
KR20170129170A (ko) 2017-11-24
TWI731853B (zh) 2021-07-01
US11090296B2 (en) 2021-08-17
KR20230104762A (ko) 2023-07-10
CN107427587A (zh) 2017-12-01
AR105947A1 (es) 2017-11-29
HK1245083A1 (zh) 2018-08-24
ES2969514T3 (es) 2024-05-21
EP3272362A4 (en) 2018-12-05
CA2979971A1 (en) 2016-09-22
EP3272362A1 (en) 2018-01-24
TW201639569A (zh) 2016-11-16
WO2016148228A1 (ja) 2016-09-22
EP3272362B1 (en) 2023-12-13
RU2017134354A (ru) 2019-04-03

Similar Documents

Publication Publication Date Title
IL265360B (en) Pharmaceutical composition
IL265260B (en) pharmaceutical preparations
GB201506658D0 (en) Pharmaceutical compounds
GB201504675D0 (en) Pharmaceutical compounds
GB201517217D0 (en) Pharmaceutical compounds
GB201506660D0 (en) Pharmaceutical compounds
GB201517216D0 (en) Pharmaceutical compounds
IL262654A (en) Pharmacy preparation
IL265349A (en) Pharmaceutical composition
HK1246641A1 (zh) 緩釋性醫藥組合物
GB201506933D0 (en) Pharmaceutical compounds
GB201502567D0 (en) Pharmaceutical compounds
IL263040A (en) Pharmaceutical composition comprising eteplirsen
GB201521462D0 (en) Pharmaceutical composition
GB201515310D0 (en) Pharmaceutical composition
HK1245073A1 (zh) 藥物組合物
PL3454838T3 (pl) Kompozycja farmaceutyczna
GB201615917D0 (en) Pharmaceutical composition
GB201520862D0 (en) Pharmaceutical composition
RS61548B1 (sr) Farmaceutski sastav sa produženim oslobađanjem koji sadrži rivastigmin
GB201615910D0 (en) Pharmaceutical composition
GB201615914D0 (en) Pharmaceutical composition
IL265436B (en) Pharmacy preparation
HUE057830T2 (hu) Famitinib tartalmú gyógyszerkészítmény
IL265428A (en) Pharmaceutical composition